№ files_lp_3_process_9_31232
File format: docx
Character count: 3274
File size: 67 KB
This document provides detailed instructions for completing the COVID-19 Long-term Care Facility Resident Therapeutics Form, including reporting requirements for therapeutic treatments administered to residents in long-term care facilities.
Year:
2021
Region / City:
United States
Topic:
Healthcare, COVID-19, Long-term Care Facilities
Document Type:
Instructional Guide
Organization:
Centers for Disease Control and Prevention (CDC)
Author:
Centers for Disease Control and Prevention (CDC)
Target Audience:
Healthcare Providers, Long-term Care Facilities
Effective Period:
January 2021
Approval Date:
January 2021
Modification Date:
None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Facility ID
Year:
Not specified
Country:
United States
Document Type:
Surveillance reporting form
Subject:
Laboratory-identified MDRO or Clostridioides difficile infection events
Applicable Setting:
Long-term care facility (LTCF)
Issuing Authority:
Centers for Disease Control and Prevention (CDC)
Legal Framework:
Public Health Service Act Sections 304, 306 and 308(d) (42 USC 242b, 242k, 242m(d))
OMB Control Number:
0920-0666
Form Number:
CDC 57.138
Revision:
rev 4, v9.4
Estimated Reporting Burden:
15 minutes per response
Data Collected:
Resident identifiers, admission dates, organism type, specimen details, care location, transfer status, antibiotic therapy, demographic information
Confidentiality Statement:
Information collected under guarantee of strict confidence for public health surveillance purposes
Year:
Not specified
Month/Year:
To be completed by facility
Facility ID:
To be completed by facility
Document Type:
Monthly reporting form
Subject:
Healthcare Associated Infection (HAI) surveillance and prevention measures
Infection Types:
UTI; Laboratory-identified Event (LabID Event)
Organism Data:
Specific Organism Type; All Specimens
Prevention Measures:
Hand Hygiene; Gown and Gloves Use
COVID-19 Module:
Healthcare Personnel COVID-19 Vaccination Summary; Resident COVID-19 Vaccination Summary
Scope:
Facility-wide Inpatient (FacWideIN)
Confidentiality Basis:
Public Health Service Act Sections 304, 306 and 308(d) (42 USC 242b, 242k, 242m(d))
Responsible Authority:
Centers for Disease Control and Prevention (CDC)
OMB Control Number:
0920-0666
Form Number:
CDC 57.141 (Front), v7.0
Estimated Reporting Burden:
5 minutes per response
Submission Contact:
CDC Project Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333
Note:
Facility ID
Event Type:
UTI
Year:
2026
Region / City:
United States
Theme:
Healthcare / Infection Control
Document Type:
Medical Record
Organization / Institution:
CDC
Author:
CDC
Target Audience:
Healthcare Providers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Last Modification:
Not specified
Year:
2025
Region / City:
Singapore
Topic:
Target Validation, Drug Discovery
Document Type:
Call for Proposals
Organization:
Singapore Therapeutics Development Review (STDR)
Author:
N/A
Target Audience:
Researchers, Principal Investigators, Institutions
Period of Action:
2025
Approval Date:
N/A
Date of Last Changes:
N/A
Year:
2024
Region:
Africa
Document type:
Call for Expression of Interest (EOI)
Issuing organizations:
Africa CDC, Unitaid
Target audience:
Pharmaceutical manufacturers, CDMOs, CROs in Africa
Programmatic focus:
Maternal health, malaria, HIV, and related co-infections
Submission deadline:
August 15, 2024
Question deadline:
July 30, 2024
Issue date:
July 8, 2024
Supported interventions:
Safe Birth Africa project co-funded by European Union
Scope:
Regional manufacturing of therapeutics, diagnostics, and APIs
Product categories:
Oral solid dosage forms, sterile injectables, APIs
Year:
Not specified
Region / city:
Not specified
Theme:
Parkinson’s disease, therapeutic research
Document Type:
Pre-Clinical Proposal Template
Organization / Institution:
Michael J. Fox Foundation
Author:
Not specified
Period of validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Date:
April 22nd, 2025
Region / City:
Paris, France
Subject:
Immuno-oncology, Biotechnology
Document Type:
Press Release
Organization / Institution:
Egle Therapeutics
Author:
Egle Therapeutics
Target Audience:
Medical and scientific professionals in immuno-oncology and biotechnology
Period of Activity:
2025
Date of Approval:
April 22nd, 2025
Date of Changes:
N/A
Year:
Not specified
Region / city:
Not specified
Document Type:
Request for Applications
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers in Parkinson’s disease therapeutics
Period of validity:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2024
Region / city:
United States
Subject:
COVID-19 therapeutics development
Document type:
Request for Proposals (RFP)
Organ / institution:
Biomedical Advanced Research and Development Authority (BARDA)
Author:
Biomedical Advanced Research and Development Authority (BARDA)
Target audience:
Product developers, biomedical organizations
Period of validity:
2024–2027
Approval date:
05 August 2024
Amendment date:
20 August 2024
Note:
Year
Topic:
Neurology, Parkinson’s Disease
Document Type:
Request for Applications
Note:
Year
Subject:
Gene Transfer, Targeting, and Therapeutics
Document Type:
Request Form
Organization / Institution:
Salk Institute
Target Audience:
Researchers and Lab personnel
Context:
A form for requesting viral vectors from the Gene Transfer, Targeting, and Therapeutics Facility at the Salk Institute for scientific research purposes.
Year:
2026
Region / City:
La Jolla, CA
Topic:
Gene Transfer, Viral Vectors
Document Type:
Request Form
Organization / Institution:
Salk Institute for Biological Studies
Author:
GT3 Core Facility
Target Audience:
Researchers, Investigators
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2013
Region / city:
Gauteng Province
Theme:
Pharmaceuticals, Therapeutics, Rational Medicine Use
Document type:
Educational material
Institution:
Management Sciences for Health (MSH)
Author:
Management Sciences for Health
Target audience:
Healthcare practitioners, policy makers, and managers
Period of validity:
Indefinite
Approval date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / city:
United States
Theme:
Gastrointestinal pharmacology, infectious diseases, antibiotic resistance, healthcare management
Document Type:
Review
Institution:
Hackensack Palisades Medical Center, Augusta University
Author:
Nagesh VK, Tran HHV, Elias D, Kianifar Aguilar I, Sethi T, Menon A, Mansour C, Furman F, Tsotsos K, Subar T, Auda A, Sidiqui A, Lamar J, Wadhwani N, Dey S, Lo A, Atoot A, Weissman S, Sifuentes H, Bangolo AI
Target Audience:
Healthcare professionals, researchers, medical practitioners
Period of Validity:
Ongoing studies, review is relevant until new treatments emerge
Date of Approval:
2024-07-25
Date of Changes:
2024-07-21
Facility:
Gene Transfer, Targeting and Therapeutics Facility
Institution:
Salk Institute for Biological Studies
Document Type:
Viral Vector Request Form
Subject:
Stock Reporter Viral Vectors
Submission Method:
Email to [email protected]
Required Information:
Principal Investigator, Lab Contact, Order Date, Fund Number or PO Number, Billing and Shipping Address
Aliquot Size AAV:
25 µl
Aliquot Size Lentiviral, Retroviral, Rabies:
5 µl
Vector Categories:
rAAV, Cre, DIO, FLEX, DO, Lentivirus, AAV Serotype Kits
Source References:
Addgene; Deisseroth Lab (Stanford University)
Material Transfer Requirement:
MTA required for Deisseroth Lab vectors
Titer Information:
Representative lot titers provided; actual titers may vary
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified